Research and Markets: Trends in Health Technology Assessment - How is Advice Provided by HTA Organizations Used by Differe

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Trends in Health Technology Assessment" report to their offering.

The report explores approaches to HTA, profiles HTA organizations in six countries (Australia, Canada, France, Germany, the UK, and the US) and examines how their results are used to inform pricing and reimbursement decisions. The focus is on pharmaceuticals, medical devices, and diagnostics and how the rapidly evolving HTA environment will influence future market access of these technologies.

Features and Benefits:

  • Analyze what evidence is required for HTA evaluations to show that a particular drug/medtech product represents an improvement on current practice.
  • Gain an insight into HTA programs & identify common trends in assessment practices and areas where there are differences in processes and procedures.
  • Evaluate how P&R policies are influenced by HTA outcomes and what impact HTA advice has on payors and providers, supported by case studies.
  • Assess industry's role in providing evidence that meets diverse HTA demands.
  • Evaluate how interaction between regulators and payors could pave the way for greater synergies between regulatory and HTA requirements.


Clinical and cost effectiveness are assessed for pharmaceuticals in Australia, Canada and the UK, while clinical benefit is the main focus in France and Germany for new drugs. CER is rapidly gaining momentum in the US to inform federal funding decisions, while commercial US payors use clinical and economic evidence in formulary listings.

Patient input is gaining greater significance in HTA, helping to provide a broader perspective of a product's value in the real world setting. By February 2011, 22 drugs had benefited from the new process for patient group input during the Canadian Common Drug Review since it was introduced in May 2010.

From January 2011, the clinical benefit of all new pharmaceuticals launched in Germany must be assessed on the basis on manufacturers' dossiers. The introduction of value-based pricing in the UK in 2014 will require all new brand medicines to demonstrate value, replacing the current system of selective appraisals by NICE.

Your Key Questions Answered:

  • What factors are used by different HTA bodies to measure the costs and benefits of health technologies?
  • How is advice provided by HTA organizations used by different payors?
  • How can companies best approach the need to incorporate HTA requirements into their product development plans?
  • What are the key challenges of HTA and what efforts are underway to address theses?
  • Which organizations are involved in HTA in Australia, Canada, France, Germany, the UK, and the US?

Key Topics Covered:

  • Executive Summary
  • About the author
  • Overview of health technology assessment
  • National HTA organizations profiled
  • HTA in practice
  • Influence of HTA on pricing and reimbursement
  • Industry's role in HTA
  • Future perspectives
  • Appendix

For more information visit

Source: Business Insights


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Biotechnology  General Health